human anti-erbB2 mAbs (AstraZeneca/Amgen)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namehuman anti-erbB2 mAbs (AstraZeneca/Amgen)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulators
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca PlcAmgen Inc
Active IndicationsN/A
Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A